|
|
|
|
X4 Pharmaceuticals Inc (NASDAQ: XFOR) |
|
|
|
| |
X4 Pharmaceuticals Inc's Total Debt to Equity
XFOR's quarterly Total Debt to Equity and Total Debt, Equity growth
|
Select the Comparisons :
|
|
Select the Ratio:
|
|
| XFOR Total Debt to Equity |
(Mar 31 2025)
Q1 |
(Dec 31 2024)
Q4 |
(Sep 30 2024)
Q3 |
(Jun 30 2024)
Q2 |
(Mar 31 2024)
Q1 |
| Y / Y Equity Change |
2114.67 % |
-67.23 % |
-11.72 % |
82.78 % |
-98.6 % |
| Y / Y Total Debt Change |
- |
- |
- |
- |
- |
| Total Debt to Equity MRQ |
- |
- |
- |
- |
- |
| XFOR's Total
Ranking |
# |
# |
# |
# |
# |
| Seq. Equity Change |
3.59 % |
-62.85 % |
-36.88 % |
9016.89 % |
-98.47 % |
| Seq. Total Debt Change |
- |
- |
- |
- |
- |
| Total Debt to Equity first quarter 2025 Company Ranking |
| Within: |
No. |
| Biotechnology & Pharmaceuticals Industry |
# |
| Healthcare Sector |
# |
| Overall Market |
# |
| Total Debt to Equity Statistics |
| High |
Average |
Low |
| 0 |
0 |
0 |
|
|
|
Cumulative X4 Pharmaceuticals Inc's Total Debt to Equity
XFOR's Total Debt to Equity for the trailling 12 Months
XFOR Total Debt to Equity |
(Mar 31 2025)
12 Months |
(Dec 31 2024)
12 Months |
(Sep 30 2024)
12 Months |
(Jun 30 2024)
12 Months |
(Mar 31 2024)
12 Months |
| Y / Y Equity TTM Growth |
6.03 % |
-32.05 % |
-12.7 % |
5.96 % |
-12.91 % |
| Y / Y Total Debt TTM Growth |
- |
- |
- |
-96.96 % |
-95.29 % |
| Total Debt to Equity TTM |
- |
- |
- |
0 |
0.01 |
| Total Ranking TTM |
|
|
| #
| #
|
| Seq. Equity TTM Growth |
12.36 % |
-20.41 % |
-3.43 % |
22.77 % |
-27.99 % |
| Seq. Total Debt TTM Growth |
- |
- |
- |
-42.03 % |
-49.94 % |
On the trailing twelve months basis During the twelve months ending Q1 2025 X4 Pharmaceuticals Inc did not have Total Debt . Total Debt to Equity is the average cumulative value over the last four quarters.
Among companies in the Biotechnology & Pharmaceuticals industry XFOR recorded the lowest Total Debt to Equity. While total ranking remained unchanged compared to previous 12 month period at no. 0.
Explain Debt to Equity Ratio?
How much Total Debts XFOR´s has?
What are XFOR´s Equity?
| TTM Total Debt to Equity Company Ranking |
| Within: |
No. |
| Within the Biotechnology & Pharmaceuticals Industry |
# |
| Healthcare Sector |
# |
| Within the Market |
# |
| trailing twelve months Total Debt to Equity Statistics |
| High |
Average |
Low |
| 0 |
0 |
0 | |
|
|
| Companies with similar Total Debt to Equity in the quarter ending Mar 31 2025, within Biotechnology & Pharmaceuticals Industry | Total Debt to Equity | Mar 31 2025 MRQ Total Debt | Mar 31 2025 MRQ Equity |
|
Date modified: 2025-05-23T09:22:02+00:00
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Copyright © 2025 CSIMarket, Inc. All rights
reserved.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
